AACE/ACE/AME Guidelines

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ASSOCIAZIONE MEDICI ENDOCRINOLOGI MEDICAL GUIDELINES FOR CLINICAL PRACTICE FOR THE DIAGNOSIS AND MANAGEMENT OF THYROID NODULES – 2016 UPDATE

EXECUTIVE SUMMARY OF RECOMMENDATIONS

Complete guidelines are available at https://www.aace.com/publications/guidelines

Hossein Gharib, MD, MACP, MACE¹, Co-Chair; Enrico Papini, MD, FACE², Co-Chair; Jeffrey R. Garber, MD, FACP, FACE³; Daniel S. Duick, MD, FACP, FACE⁴; R. Mack Harrell, MD, FACP, FACE, ECNU⁵; Laszlo Hegedüs, MD⁶; Ralf Paschke, MD⁷; Roberto Valcavi, MD, FACE⁸; Paolo Vitti, MD⁹; on behalf of the AACE/ACE/AME Task Force on Thyroid Nodules*

American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE) and Associazione Medici Endocrinologi (AME) Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules are systematically developed statements to assist health care professionals in medical decision making for specific clinical conditions. Most of the content herein is based on literature reviews. In areas of uncertainty, professional judgment was applied.

The first edition of the AACE/ACE/AME Guidelines for the Diagnosis and Management of Thyroid Nodules was published in 2006 after extensive review of the literature by representatives of endocrinologists, endocrine surgeons, and thyroid pathologists and with accurate external refereeing. These guidelines were updated in 2010 by a task-force group representing experts from the same scientific societies and from the European Thyroid Association on the basis of advances in diagnosis and management of thyroid nodules. The Task Force now editing this third edition of the guidelines on behalf of AACE/ACE/AME includes new contributors and referees. This updated edition incorporates recent scientific evidence, includes the use of new diagnostic tools and treatments, and addresses avoiding unnecessary diagnostic procedures and risk of medical or surgical overtreatment. The importance of patient information and participation in clinical decision making and the role of a multidisciplinary approach to thyroid nodular disease are fully considered.

These guidelines are a working document that reflects the state of the field at the time of publication. Because rapid changes in this area are expected, periodic revision is inevitable. We encourage medical professionals to use this information in conjunction with their best clinical judgment. Any decision by practitioners to apply these guidelines must be made in light of local resources and individual patient circumstances and preference.

Copyright © 2016 AACE.
Abbreviations:
AACE = American Association of Clinical Endocrinologists; ACE = American College of Endocrinology; AME = Associazione Medici Endocrinologi; BEL = best evidence level; CNB = core-needle biopsy; CT = computed tomography; FNA = fine-needle aspiration; FT\(_4\) = free triiodothyronine; FT\(_3\) = free thyroxine; LT\(_4\) = levothyroxine; MeSH = Medical Subject Headings; MNG = multinodular goiter; MRI = magnetic resonance imaging; PEI = percutaneous ethanol injection; PET = positron emission tomography; Tg = thyroglobulin; TIRADS = Thyroid Imaging Reporting and Data System; TPOAb = antithyroid peroxidase antibody; TSH = thyrotropin (thyroid-stimulating hormone); US = ultrasonography, ultrasonographic.

ABSTRACT

Thyroid nodules are detected in up to 50 to 60% of healthy subjects. Most nodules do not cause clinically significant symptoms, and as a result, the main challenge in their management is to rule out malignancy, with ultrasonography (US) and fine-needle aspiration (FNA) biopsy serving as diagnostic cornerstones. The key issues discussed in these guidelines are as follows: (1) US-based categorization of the malignancy risk and indications for US-guided FNA (henceforth, FNA), (2) cytologic classification of FNA samples, (3) the roles of immunocytochemistry and molecular testing applied to thyroid FNA, (4) therapeutic options, and (5) follow-up strategy. Thyroid nodule management during pregnancy and in children are also addressed. On the basis of US features, thyroid nodules may be categorized into 3 groups: low-, intermediate- and high-malignancy risk. FNA should be considered for nodules ≤10 mm diameter only when suspicious US signs are present, while nodules ≤5 mm should be monitored rather than biopsied. A classification scheme of 5 categories (non-diagnostic, benign, indeterminate, suspicious for malignancy, or malignant) is recommended for the cytologic report. Indeterminate lesions are further subdivided into 2 subclasses to more accurately stratify the risk of malignancy. At present, no single cytochemical or genetic marker can definitely rule out malignancy in indeterminate nodules. Nevertheless, these tools should be considered together with clinical data, US signs, elastographic pattern, or results of other imaging techniques to improve the management of these lesions. Most thyroid nodules do not require any treatment, and levothyroxine (LT\(_4\)) suppressive therapy is not recommended. Percutaneous ethanol injection (PEI) should be the first-line treatment option for relapsing, benign cystic lesions, while US-guided thermal ablation treatments may be considered for solid or mixed symptomatic benign thyroid nodules. Surgery remains the treatment of choice for malignant or suspicious nodules. The present document updates previous guidelines released in 2006 and 2010 by the American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE) and Associazione Medici Endocrinologi (AME). (Endocr Pract. 2016;22:622-639)

I. INTRODUCTION

This document was prepared as a collaborative effort between the American Association of Clinical Endocrinologists (AACE), American College of Endocrinology (ACE) and Associazione Medici Endocrinologi (AME), Associazione Medici Endocrinologi). These guidelines cover diagnostic and therapeutic aspects of thyroid nodular disease but not thyroid cancer management. Suggestions for thyroid nodule management during pregnancy and childhood are also presented herein. The AACE protocol for standardized production of clinical practice guidelines was followed to rate the evidence level of each reference and to link the guidelines to the strength of recommendations (see Methods).

The basis of thyroid nodule management is the use of high-resolution ultrasonography (US), sensitive thyrotropin (TSH, formerly thyroid-stimulating hormone) assay, and fine-needle aspiration (FNA) biopsy, together with clinical findings. Thyroid scintigraphy is not necessary for diagnosis in most cases; however, it may be warranted in patients with a low serum TSH value or a
multinodular gland to detect functional autonomy, most common in iodine-deficient areas. Measurement of serum TSH is the best initial laboratory test of thyroid function and should be followed by measurement of free thyroxine (FT$_4$) and free triiodothyronine (FT$_3$) when the TSH value is decreased, and measurement of thyroid peroxidase antibodies (TPOAbs) and FT$_3$ when the TSH value is above the reference range. A single, nonstimulated serum calcitonin measurement should be performed only when medullary thyroid carcinoma (MTC) is suspected due to FNA results or history.

Thyroid nodules are a common finding because they are detected in up to 50 to 60% of healthy people. In most cases, they appear in euthyroid persons and cause neither compressive symptoms nor cosmetic concerns. Accordingly, the main clinical challenge in the treatment of these patients is to rule out malignancy. Most patients with thyroid nodules are asymptomatic, but the absence of symptoms does not rule out malignancy. Thus, clinical and US risk factors for malignant disease should always be reviewed. All patients with a palpable thyroid nodule or clinical risk factors should undergo US examination.

Thyroid FNA should always be performed under US guidance because it makes the procedure safer, more reliable, and more accurate. In light of the low clinical risk, nodules <5 mm should always be monitored with US rather than biopsied. FNA should be considered for nodules with a major diameter ≤5-10 mm only when suspicious US signs are present (high US risk thyroid lesions) in association with pathologic lymph nodes or extrathyroidal spread. FNA is also appropriate in cases where the patient has a personal or family history of thyroid cancer or of coexistent suspicious clinical or imaging findings. FNA should be performed on nodules >10 mm that are devoid of suspicious US and/or clinical findings yet do not show a definite benign appearance (intermediate US risk thyroid lesions). Finally, FNA should be performed on spongiform, isohyperechoic, or predominantly (>50%) cystic nodules in the absence of suspicious US findings (low US risk thyroid lesions) only when nodules are ≥20 mm or progressively increasing in size. Nodules that are functioning on scintigraphy and devoid of suspicious US features can be excluded from FNA.

A classification scheme of 5 cytologic diagnostic categories and 2 subcategories is recommended for the cytologic report: nondiagnostic, benign, indeterminate, suspicious for malignancy, or malignant. Indeterminate lesions are further subdivided into 2 subclasses with significantly different estimated risks of cancer, to better stratify the risk of malignancy associated with the “indeterminate” nodules.

Nondiagnostic aspirates composed of pure colloid and obtained from a nodule that is completely cystic on US should be labeled as compatible with a colloid cyst and require clinical and US follow-up. Solid, persistently nondiagnostic nodules may be considered for US-guided core-needle biopsy (CNB) for microhistologic assessment. Alternatively, those with clearly favorable clinical and US findings can be monitored with close surveillance, whereas suspicious lesions should be surgically resected.

Nodules with benign cytologic characteristics should undergo clinical and US follow-up. A repeat FNA should be performed in the case of suspicious clinical and/or US findings or with substantial and progressive nodule enlargement, defined as a volume increase >50% (greater than the interobserver coefficient of variation). Most patients with benign thyroid nodules do not require any treatment; levothyroxine (LT$_4$) suppressive therapy is not recommended in euthyroid patients. In iodine-deficient geographic regions, iodine supplementation is recommended, and a trial of non-TSH-suppressive treatment with LT$_4$ may be considered in young patients with a small nodular goiter. Symptomatic goiters, whether euthyroid or hyperthyroid, may be treated surgically or with radiiodine. Percutaneous ethanol injection (PEI) is the first-line treatment of relapsing benign cystic thyroid lesions. In patients with solid or complex, symptomatic or progressively enlarging benign thyroid nodules, US-guided thermal ablation treatments may effectively control nodule growth and local symptoms.

Malignant or suspicious nodules should be treated surgically. Preoperative evaluation with US, FNA, and, if needed, further imaging techniques, is recommended for appropriate surgical planning.

In nodules with indeterminate cytologic results, no single cytochemical or genetic marker is specific or sensitive enough to rule out malignancy with certainty. However, the use of immunohistochemical and molecular markers may be considered together with the cytologic subcategories and data from US, elastography, or other imaging techniques to obtain additional information for management of these patients.

In selected cases (e.g., neck masses suspicious for lymph node metastasis from thyroid cancer, enlarged parathyroid glands), hormone measurement in the needle washouts increases FNA diagnostic accuracy.

These guidelines provide information to improve the management of patients with thyroid nodules. These recommendations must always take into account available local expertise, the clinical setting, and patient preference.

II. METHODS

Development and Use of the Guidelines: Methods of Bibliographic Research

We searched for primary evidence to support the current guidelines by using a “clinical question” method. Each topic covered by the guidelines was translated to a related question. Accordingly, the bibliographic research was conducted by selecting studies able to yield a methodologically reliable answer to each question. The first step was to select pertinent published reports. The U.S. National
Guidelines were searched in the following databases: National Guideline Clearinghouse (U.S.); Agency for Healthcare Research and Quality (U.S.); Canadian Medical Association–Clinical Practice Guidelines; Canadian Task Force on Preventive Health Care; National Institutes of Health–National Heart, Lung, and Blood Institute (U.S.); National Health Service Research and Development Health Technology Assessment Programme (UK); National Institute of Clinical Excellence (UK); New Zealand Guidelines Group; PRODIGY Guidance–National Health Service (UK); and the Scottish Intercollegiate Guidelines Network.

Levels of Evidence and Grading of Recommendations

The AACE protocol for standardized production of clinical practice guidelines was followed to rate the evidence level of each reference on a scale of 1 to 4 and to link the guidelines to the strength of recommendations on the basis of grade designations A (action based on strong evidence) through D (action not based on any evidence or not recommended) (Table 1) (4 [EL 4-guidelines]). The BEL, corresponding to the best conclusive evidence found, accompanies the recommendation grade (5 [EL 4]). All recommendations resulted from a consensus among the AACE and AME primary writers and were influenced by input from the Task Force members and reviewers. Some recommendations were upgraded or downgraded on the basis of expert opinion. In these cases, subjective factors such as clinical experience, cost, risk, and regional availability of specific technologies and expertise took priority over the reported BEL.

III. EXECUTIVE SUMMARY

A. SECTIONS

To guide readers, the 2016 Clinical Practice Guidelines for the Diagnosis and Management of Thyroid Nodules are divided into the following sections:

- The Scope of the Problem
- Clinical Evaluation and Diagnosis
- Thyroid Ultrasonography and Other Diagnostic Imaging Studies
- Thyroid Biopsy
- Laboratory Evaluation
- Radionuclide Scanning
- Management and Therapy
- Thyroid Nodules during Pregnancy
- Management of Thyroid Nodules in Children

Readers are referred to the Appendix for more detail and supporting evidence for each section.
<table>
<thead>
<tr>
<th>Level of evidence</th>
<th>Description</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Well-controlled, generalizable, randomized trials</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adequately powered, well-controlled multicenter trials</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Large meta-analyses with quality ratings</td>
<td></td>
</tr>
<tr>
<td></td>
<td>All-or-none evidence</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>Randomized controlled trials with limited body of data</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Well-conducted prospective cohort studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Well-conducted meta-analyses of cohort studies</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Methodologically flawed randomized clinical trials</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Observational studies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Case series or case reports</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conflicting evidence, with weight of evidence supporting the recommendation</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>Expert consensus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Expert opinion based on experience</td>
<td></td>
</tr>
<tr>
<td></td>
<td>“Theory-driven conclusions”</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unproven claims</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Level of evidence</th>
<th>Description</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>&gt;1 Conclusive level 1 publications demonstrating benefit &gt;&gt; risk</td>
<td>Action recommended for indications reflected by published reports</td>
</tr>
<tr>
<td></td>
<td>Action based on strong evidence</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Action can be used with other conventional therapy or as first-line therapy</td>
</tr>
<tr>
<td>B</td>
<td>No conclusive level 1 publication</td>
<td>Action recommended for indications reflected by the published reports</td>
</tr>
<tr>
<td></td>
<td>≥1 Conclusive level 2 publications demonstrating benefit &gt;&gt; risk</td>
<td>Use if the patient declines or does not respond to conventional therapy; must monitor for adverse effects</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Action based on intermediate evidence</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Can be recommended as “second-line” therapy</td>
</tr>
<tr>
<td>C</td>
<td>No conclusive level 1 or 2 publications</td>
<td>Action recommended for indications reflected by the published reports</td>
</tr>
<tr>
<td></td>
<td>≥1 Conclusive level 3 publication demonstrating benefit &gt;&gt; risk</td>
<td>Use when the patient declines or does not respond to conventional therapy, provided there are no important adverse effects;</td>
</tr>
<tr>
<td></td>
<td>Or</td>
<td></td>
</tr>
<tr>
<td></td>
<td>No conclusive risk at all and no benefit at all</td>
<td>“No objection” to recommending their use</td>
</tr>
<tr>
<td></td>
<td>Or</td>
<td>“No objection” to continuing their use</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Action based on weak evidence</td>
</tr>
<tr>
<td>D</td>
<td>No conclusive level 1, 2, or 3 publication demonstrating benefit &gt;&gt; risk</td>
<td>Not recommended</td>
</tr>
<tr>
<td></td>
<td>Patient is advised to discontinue use</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conclusive level 1, 2, or 3 publication demonstrating risk &gt;&gt; benefit</td>
<td>Action not based on any evidence</td>
</tr>
</tbody>
</table>

\(^a\) Adapted from Mechanick et al (366) and Mechanick et al (367). Used with permission.
B. SUMMARY OF RECOMMENDATIONS

1. Thyroid Nodules: The Scope of the Problem
   • These guidelines are designed to optimize the current clinical practice in the diagnosis and management of thyroid nodules and nodular goiters.
   • The recommendations should always be applied considering clinical setting, local medical expertise, available technical resources, and patient preferences [BEL 3, GRADE B].

2. Clinical Evaluation and Diagnosis
   2.1. History
      • We recommend that the following data be recorded:
        Age
        Personal or family history of thyroid disease or cancer
        Previous head or neck irradiation
        Rate of neck mass growth
        Anterior neck pain
        Dysphonia, dysphagia, or dyspnea
        Symptoms of hyper- or hypothyroidism
        Use of iodine-containing drugs or supplements [BEL 2, GRADE A]
      • Most nodules are asymptomatic and benign, but the absence of symptoms does not rule out malignancy [BEL 2, GRADE A].

   2.2. Physical Examination
      • We recommend a careful, focused examination of the thyroid gland and cervical lymph nodes [BEL 3, GRADE B].
      • Record the following data:
        Thyroid volume and consistency
        Location, consistency, size, and number of nodule(s)
        Neck tenderness or pain
        Cervical adenopathy [BEL 3, GRADE B]
      • The risk of cancer is not substantially different in patients with a solitary nodule versus patients with a multinodular goiter (MNG) [BEL 2, GRADE B].

3. Thyroid Ultrasonography and Other Diagnostic Imaging Studies
   3.1. When to Perform Thyroid US
      • US evaluation is recommended for patients who are at risk for thyroid malignancy (see Table 3), have palpable thyroid nodules or goiter, or have neck lymphadenopathy suggestive of a malignant lesion [BEL 2, GRADE A].
      • US evaluation is not recommended as a screening test for the general population or patients with a normal thyroid on palpation and a low clinical risk of thyroid disease [BEL 4, GRADE C].

3.2. How to Describe US Findings
   We recommend the following approach to describe US findings:
      • Focus the US report on stratification for risk of malignancy
      • Describe position, size, shape, margins, content, echogenic pattern, and vascular features of the nodule(s)
   • For multiple nodules, detail the nodule(s) bearing the US characteristics associated with malignancy rather than describing the largest (dominant) nodule.

---

### Table 2
Comparison of the Italian AME Consensus, BSRTC, and UK-RCPath Systems for Classification and Reporting of Thyroid Cytologic Results

<table>
<thead>
<tr>
<th>Italian Consensus, 2014</th>
<th>BSRTC</th>
<th>UK-RCPath</th>
</tr>
</thead>
<tbody>
<tr>
<td>TIR 1. Nondiagnostic</td>
<td>I. Nondiagnostic</td>
<td>Thy 1. Nondiagnostic</td>
</tr>
<tr>
<td>TIR 1c. Nondiagnostic cystic</td>
<td>I. Cystic fluid only</td>
<td>Thy 1c. Unsatisfactory, consistent with cyst</td>
</tr>
<tr>
<td>TIR 2. Nonmalignant</td>
<td>II. Benign</td>
<td>Thy 2/Thy 2c. Nonneoplastic</td>
</tr>
<tr>
<td>TIR 3A. Low-risk indeterminate lesion</td>
<td>III. AUS/FLUS atypia or follicular lesion of undetermined significance</td>
<td>Thy 3a. Neoplasm possible: atypia/ nondiagnostic</td>
</tr>
<tr>
<td>TIR 3B. High-risk indeterminate lesion</td>
<td>IV. Follicular neoplasm or suspicious for follicular neoplasm</td>
<td>Thy 3f. Neoplasm possible: suggestive of follicular neoplasm</td>
</tr>
<tr>
<td>TIR 4. Suspicious for malignancy</td>
<td>V. Suspicious for malignancy</td>
<td>Thy 4. Suspicious for malignancy</td>
</tr>
<tr>
<td>TIR 5. Malignant</td>
<td>VI. Malignant</td>
<td>Thy 5. Malignant</td>
</tr>
</tbody>
</table>

Abbreviations: AME = Associazione Medici Endocrinologi; AUS/FLUS = follicular lesion/atypia of undetermined significance; BSRTC = Bethesda System for Reporting Thyroid Cytopathology; TIR = Thyroid Imaging Reporting; Thy = thyroid; UK-RCPath = UK Royal College of Pathologists.
• For suspicious regional neck lymph nodes, describe the cervical compartment, number, shape, size, margins, content, echogenic pattern, presence of hilum, and vascular features [BEL 2, GRADE A].

3.3. US Rating of the Risk of Malignancy

- In thyroid US reports, add to the description of US features a rating that stratifies thyroid lesions on the basis of their risk of malignancy to reliably communicate the expected risk of cancer (see Table 4) [BEL 3, GRADE B].

3.4. US Classification Systems

The following US rating system of the risk of malignancy is suggested (see Table 5 and Fig. 1 and 2):

- **Class 1. Low-risk thyroid lesion.**
  - Mostly cystic (>50%) nodules with reverberating artifacts that are not associated with suspicious US signs
  - Isoechoic spongiform nodules confluent or with regular halo
  - The expected risk of malignancy is about 1%.

- **Class 2. Intermediate-risk thyroid lesion.**
  - Slightly hypoechoic nodules (cf. surrounding thyroid tissue) and isoechoic nodules with ovoid-to-round shape and smooth or ill-defined margins.
  - Intranodular vascularization, elevated stiffness at elastography, macro- or continuous rim calcifications, or hyperechoic spots of uncertain significance may be present.
  - The expected risk of malignancy is 5 to 15%.

- **Class 3. High-risk thyroid lesion.** Nodules with at least 1 of the following suspicious features:
  - Marked hypoechogenicity (cf. prethyroid muscles)
  - Spiculated or microlobulated margins
  - Microcalcifications
  - Taller-than-wide shape
  - Evidence of extrathyroidal growth or pathologic adenopathy
  - The expected risk of malignancy is 50 to 90% in accordance with the presence of 1 or more suspicious findings [BEL 4, GRADE C].

3.5. Indications for US-Guided Fine-Needle Aspiration

3.5.1. **How to select nodule(s) for US-guided FNA**

- In the selection of nodules for US-guided FNA, consider a balance between the risk of a potentially delayed diagnosis and that of superfluous diagnostic procedures or surgery (see Fig. 1) [BEL 4, GRADE C].
- In light of the low clinical risk, nodules with a major diameter <5 mm should be monitored with US rather than biopsied, irrespective of their sonographic appearance [BEL 3, GRADE B].
- In nodules with a major diameter 5-10 mm that are associated with suspicious US signs (high US risk thyroid lesions), consider either FNA sampling or watchful waiting on the basis of the clinical setting and patient preference [BEL 3, GRADE B]. Specifically, US-guided FNA is recommended for the following nodules:
  - Subcapsular or paratracheal lesions
  - Suspicious lymph nodes or extrathyroid spread
  - Positive personal or family history of thyroid cancer
  - Coexistent suspicious clinical findings (e.g., dysphonia) [BEL 2, GRADE A]
- FNA is recommended for the following:
  - High US risk thyroid lesions ≥10 mm
  - Intermediate US risk thyroid lesions >20 mm
  - Low US risk thyroid lesions only when >20 mm and increasing in size or associated with a risk history and before thyroid surgery or minimally invasive ablation therapy [BEL 2, GRADE A]
- FNA is not recommended for nodules that are functional on scintigraphy (see difference in

### Table 3. Features Suggesting Increased Risk of Malignant Potential

<table>
<thead>
<tr>
<th>Feature</th>
</tr>
</thead>
<tbody>
<tr>
<td>History of head and neck irradiation</td>
</tr>
<tr>
<td>Family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, or papillary thyroid carcinoma</td>
</tr>
<tr>
<td>Age &lt;14 or &gt;70 years</td>
</tr>
<tr>
<td>Male sex</td>
</tr>
<tr>
<td>Growth of the nodule</td>
</tr>
<tr>
<td>Firm or hard nodule consistency</td>
</tr>
<tr>
<td>Cervical adenopathy</td>
</tr>
<tr>
<td>Fixed nodule</td>
</tr>
<tr>
<td>Persistent dysphonia, dysphagia, or dyspnea</td>
</tr>
</tbody>
</table>
recommendations for children; Section 8.4.) [BEL 2, GRADE B].

3.5.2. FNA of multinodular glands and lymph nodes
- We do not recommend the biopsy of more than 2 nodules in the same patient when the nodules are selected on the basis of the previously described criteria [BEL 3, GRADE C].
- If a radioisotope scan is available, we recommend not biopsying hot areas [BEL 2, GRADE B].
- In the presence of suspicious cervical lymphadenopathy, we recommend FNA for cytologic assessment of both the lymph node and the suspicious nodule(s) [BEL 2, GRADE A].
- We recommend the determination of thyroglobulin (Tg) or calcitonin, according to clinical indications, on FNA washout of suspicious lymph nodes [BEL 2, GRADE A].

3.5.3. FNA of complex thyroid nodule(s)
- We recommend sampling the solid component of the lesion through FNA biopsy [BEL 3, GRADE B].
- Preferentially sample the vascularized areas of the complex lesion [BEL 4, GRADE C].
- Submit both the FNA specimen and the drained fluid for cytologic examination [BEL 2, GRADE A].

3.5.4. FNA of thyroid incidentalomas
- Manage thyroid incidentalomas according to the previously described criteria for nodule diagnosis [BEL 2, GRADE A].
- Perform US evaluation of incidentalomas detected by computed tomography (CT) or magnetic resonance imaging (MRI) before consideration of FNA biopsy [BEL 2, GRADE A].
- We recommend that thyroid incidentalomas detected by positron emission tomography (PET) with $^{18}$F-fluorodeoxyglucose ($^{18}$FDG) (focal uptake, in particular) should undergo US evaluation and FNA because of the high risk of malignancy [BEL 2, GRADE A].

3.5.6. Other Diagnostic Imaging Techniques
- MRI and CT are not recommended for routine thyroid nodule evaluation [BEL 2, GRADE A].
- Consider MRI and CT for assessment of size, airway compression, subternal extension of a nodular goiter, or presence of pathologic lymph nodes in cervical regions not visualized by US [BEL 3, GRADE B].
- PET/CT may provide additional information about the risk of malignancy in thyroid nodules with indeterminate cytologic results. Because of the insufficient diagnostic accuracy, high cost, and limited accessibility, we do not suggest its routine use as a diagnostic tool [BEL 3, GRADE B].
- Consider PET/CT only for the preoperative staging of malignant nodules with aggressive features [BEL 3, GRADE B].

3.5.7. Other US Techniques
- Elastography provides information about nodule stiffness that is complementary to grayscale findings [BEL 2, GRADE B].
- Elastography should not be used as a substitute for grayscale US examination, but as a complementary tool in nodules with indeterminate US or cytologic findings [BEL 2, GRADE A].
- Perform FNA in nodules with increased stiffness [BEL 2, GRADE B].
- Use of US contrast medium is not recommended for the diagnostic evaluation of thyroid nodules [BEL 3, GRADE C].
- Use of US contrast medium is recommended only for the assessment of the area of tissue ablation induced by minimally invasive techniques [BEL 3, GRADE B].

4. Thyroid Biopsy
4.1. Thyroid FNA
- Combine clinical and US evaluation and, when appropriate, FNA results in the clinical management of thyroid nodules [BEL 2, GRADE A].
- Always perform thyroid FNA because cytologic diagnoses are more reliable and the nondiagnostic rates are lower than with palpation-guided FNA (see Table 6) [BEL 2, GRADE A].

4.1.1. Requisition Form
- Include all relevant clinical and US information [BEL 4, GRADE C].
- Include a rating of the US risk of malignancy, based on an acknowledged US classification system [BEL 3, GRADE B].
- Use the following 3 US rating categories: high risk, intermediate risk, and low risk [BEL 4, GRADE C].
- Clearly state the sampling site and technique and the number of submitted slides and/or other sampled specimens [BEL 3, GRADE B].

4.1.2. Cytologic Report
- Include a brief description of cytologic findings and, when possible, a conclusive cytologic diagnosis [BEL 2, GRADE A].
- Identify the cytologic result by adding a rating of the risk of malignancy based on an
established classification system for thyroid cytology [BEL 2, GRADE A].

4.2. Cytologic Diagnosis

- Define FNA results as either diagnostic (satisfactory) or nondiagnostic (unsatisfactory) [BEL 3, GRADE B].
- As a general rule, define the cytologic specimen as diagnostic when the sample contains a minimum of 6 groups of well-preserved thyroid epithelial cells consisting of at least 10 cells per group [BEL 3, GRADE B].
- Classify cytologic specimens characterized by marked atypia as suspicious, even in the absence of the required number of follicular cells for adequacy [BEL 3, GRADE B].
- Five diagnostic classes with subdivision of indeterminate samples into 2 subclasses are recommended for cytologic reports (see Table 2) [BEL 2, GRADE A].
- Use the following reporting system for thyroid cytologic characteristics:

  **Thyroid 1. Nondiagnostic.**
  - Inadequate or insufficient to make a diagnosis
  - Cystic: insufficient but consistent with a benign cystic lesion

  **Thyroid 2. Benign.**
  **Thyroid 3. Indeterminate.**
  - Atypia or follicular lesion of undetermined significance (or a similar subclass in comparable cytologic classification systems [see Table 2])
  - Follicular neoplasm or lesion suspicious for follicular neoplasm (or similar subclass in comparable cytologic classification systems [see Table 2])

  **Thyroid 4. Suspicious for malignancy.**
  **Thyroid 5. Malignant** [BEL 2, GRADE A].

4.3. FNA Pitfalls

- To decrease the risk of misleading cytologic results, consider the following:
  - False-negative results are usually due to inappropriate target selection or inadequate sampling.
  - False-positive results are usually due to specimens with suspicious, but nondiagnostic, findings [BEL 4, GRADE C].
- For indeterminate cytologic findings, consider a second opinion from an experienced cytopathologist because some of these cases may, in high-volume thyroid cytopathology units, be reassessed as definitely benign or malignant [BEL 3, GRADE C].
- To decrease the risk of false-negative results, we recommend the following:
  - Routine use of FNA

---

### Table 4

#### US Features of Benign or Malignant Thyroid Nodules

<table>
<thead>
<tr>
<th>US features indicative of a benign nodule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoechoic spongiform appearance (microcystic spaces comprising &gt;50% of the nodule)</td>
</tr>
<tr>
<td>Simple cyst with thin regular margins</td>
</tr>
<tr>
<td>Mostly cystic (&gt;50%) nodules containing colloid (hyperechoic spots with comet-tail sign)</td>
</tr>
<tr>
<td>Regular “eggshell” calcification around the periphery of a nodule</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>US features indicative of a malignant nodule</th>
</tr>
</thead>
<tbody>
<tr>
<td>Papillary carcinoma</td>
</tr>
<tr>
<td>Solid hypoechoic (relative to prethyroid muscles) nodule, which may contain hyperechoic foci without posterior shadowing (i.e., microcalcifications)</td>
</tr>
<tr>
<td>Solid hypoechoic nodule, with intranodular vascularity and absence of peripheral halo</td>
</tr>
<tr>
<td>“Taller-than-wide” nodule (AP&gt;TR diameter when imaged in the transverse plane)</td>
</tr>
<tr>
<td>Hypoechoic nodule with spiculated or lobulated margin</td>
</tr>
<tr>
<td>Hypoechoic mass with a broken calcified rim and tissue extension beyond the calcified margin</td>
</tr>
<tr>
<td>Follicular neoplasm (either follicular adenoma or carcinoma)</td>
</tr>
<tr>
<td>Isoechoic or mildly hypoechoic homogeneous nodule with intranodular vascularization and well-defined halo</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Indeterminate US features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Isoechoic or hyperechoic nodule with hypoechoic halo</td>
</tr>
<tr>
<td>Mild hypoechoic (relative to surrounding parenchyma) nodule with smooth margin</td>
</tr>
<tr>
<td>Peripheral vascularization</td>
</tr>
<tr>
<td>Intranodular macrocalcification</td>
</tr>
</tbody>
</table>

Abbreviations: AP = anteroposterior; TR = transverse; US = ultrasound.
### Table 5
Comparison of the 2016 AACE/ACE-AME, 2015 ATA, and 2014 BTA Thyroid Nodule Ultrasound Classification Systems

<table>
<thead>
<tr>
<th>AACE/ACE-AME</th>
<th>ATA</th>
<th>BTA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1 Low-risk lesion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Cysts (fluid component &gt;80%)</td>
<td>Benign</td>
<td>U2 Benign</td>
</tr>
<tr>
<td>• Mostly cystic nodules with reverberating artifacts and not associated with suspicious US signs</td>
<td>Normally cystic nodules (no solid component)</td>
<td>A. Halo, isoechoic, mildly hyperechoic</td>
</tr>
<tr>
<td>• Isoechoic spongiform nodules, either confluent or with regular halo.</td>
<td><strong>Very low suspicion</strong></td>
<td>B. Cystic change ± ring-down sign (colloid)</td>
</tr>
<tr>
<td><strong>Low suspicion</strong></td>
<td>Spongiform or partially cystic nodules without any of the US features described in low-, intermediate- or high-suspicion patterns</td>
<td>C. Microcystic/spongiform</td>
</tr>
<tr>
<td>Isoechoic or hyperechoic solid nodule, or partially cystic nodule with eccentric solid area without:</td>
<td><strong>Intermediate suspicion</strong></td>
<td>D. Peripheral eggshell calcification</td>
</tr>
<tr>
<td>• Microcalcifications</td>
<td>Hypoechoic solid nodule with smooth margins without:</td>
<td>E. Peripheral vascularity</td>
</tr>
<tr>
<td>• Irregular margin</td>
<td>• Microcalcifications</td>
<td></td>
</tr>
<tr>
<td>• Extrathyroidal extension</td>
<td>• Extrathyroidal extension</td>
<td></td>
</tr>
<tr>
<td>• Taller than wide shape</td>
<td><strong>U3 Indeterminate/equivocal</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Homogeneous, markedly hyperechoic, solid, halo (follicular lesion)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>B. Hypoechoic (?), equivocal echogenic foci, cystic change (irregular)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C. Mixed/central vascularity</td>
<td></td>
</tr>
<tr>
<td><strong>2 Intermediate-risk thyroid lesion</strong></td>
<td>Intermediate suspicion</td>
<td></td>
</tr>
<tr>
<td>Slightly hypoechoic (vs. thyroid tissue) or isoechoic nodules, with ovoid-to-round shape, smooth or ill-defined margins</td>
<td>Hypoechoic solid nodule with smooth margins without:</td>
<td></td>
</tr>
<tr>
<td>May be present:</td>
<td>• Microcalcifications</td>
<td></td>
</tr>
<tr>
<td>• Intranodular vascularization</td>
<td>• Extrathyroidal extension</td>
<td></td>
</tr>
<tr>
<td>• Elevated stiffness at elastography,</td>
<td>• Or taller than wide shape</td>
<td></td>
</tr>
<tr>
<td>• Macro or continuous rim calcifications</td>
<td><strong>U4 Suspicious</strong></td>
<td></td>
</tr>
<tr>
<td>• Indeterminate hyperechoic spots</td>
<td><strong>High suspicion</strong></td>
<td>A. Solid, hypoechoic (cf. thyroid)</td>
</tr>
<tr>
<td></td>
<td><strong>U5 Malignant</strong></td>
<td>B. Solid, very hypoechoic (cf. strap muscle)</td>
</tr>
<tr>
<td></td>
<td>Solid hypoechoic nodule or solid hypoechoic component of partially cystic nodule with 1 or more of the following features:</td>
<td>C. Disrupted peripheral calcification, hypoechoic</td>
</tr>
<tr>
<td>Nodules with at least 1 of the following features:</td>
<td>• Irregular margins (infiltrative, microlobulated)</td>
<td>D. Lobulated outline</td>
</tr>
<tr>
<td>• Marked hypoechogenicity (vs. prethyroid muscles)</td>
<td>• Microcalcifications</td>
<td></td>
</tr>
<tr>
<td>• Spiculated or lobulated margins</td>
<td>• Taller than wide shape</td>
<td></td>
</tr>
<tr>
<td>• Microcalcifications</td>
<td>• Rim calcifications with small extrusive soft tissue component</td>
<td></td>
</tr>
<tr>
<td>• Taller-than-wide shape (AP&gt;TR)</td>
<td>• Evidence of extrathyroidal extension</td>
<td></td>
</tr>
<tr>
<td>• Extrathyroidal growth</td>
<td><strong>U5 Malignant</strong></td>
<td>A. Solid, hypoechoic, lobulated/irregular outline, microcalcification (papillary carcinoma?)</td>
</tr>
<tr>
<td>• Pathologic adenopathy</td>
<td><strong>High suspicion</strong></td>
<td>B. Solid, hypoechoic, lobulated/irregular outline, globular calcification (medullary carcinoma?)</td>
</tr>
<tr>
<td><strong>Expected risk of malignancy in accordance with the presence of 1 or more suspicious findings.</strong></td>
<td><strong>U5 Malignant</strong></td>
<td>C. Intranodular vascularity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>D. Shape tall&gt;wide (AP&gt;TR)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>E. Characteristic associated lymphadenopathy</td>
</tr>
</tbody>
</table>

Abbreviations: AACE/ACE/AME = American Association of Clinical Endocrinologists/American College of Endocrinology/Associazione Medici Endocrinologi; AP = anteroposterior; ATA = American Thyroid Association; BTA = British Thyroid Association; TR = transverse; US = ultrasonography.

Aspiration of at least 2 sites within the nodule

For multiple nodules, prioritize nodules to be sampled according to US findings.

For cystic lesions, sample solid or vascularized areas with FNA and submit cyst fluid for cytologic examination.

Review of the slides with an experienced cytopathologist

Follow-up on benign nodule(s)

Repeat FNA in benign nodules with suspicious clinical or US findings.

In large-sized thyroid lesions, sample peripheral and, possibly, solid areas to avoid fluid or necrotic zones [BEL 3, GRADE B].

4.3.1. Thyroglobulin and Hormone Measurement on FNA Washout

- Measurement of Tg, calcitonin, or parathyroid hormone (PTH) levels on FNA washout of suspicious thyroid lesions or lymph nodes is recommended when clinically appropriate [BEL 2, GRADE A].
- Each center should determine its own reference range for hormone measurement from FNA washout samples [BEL 3, GRADE B].

4.4. Core-Needle Biopsy

- Consider the use of US-guided core-needle biopsy (CNB) in solid thyroid nodules with persistently inadequate FNA cytologic findings [BEL 3, GRADE C].
- Because of the limited evidence and the lack of established reporting systems, we do not recommend either in favor of or against the use of CNB in nodules with indeterminate cytologic results [BEL 4, GRADE D].

4.5. Immunocytochemistry

- Immunocytochemistry is suggested for lesions that are suspected to be of nonfollicular origin (e.g., parathyroid gland, medullary thyroid carcinoma, lymphoma, metastases from other organs) [BEL 3, GRADE B].

4.6. Molecular Testing

4.6.1. When molecular testing should be considered

- To complement rather than replace cytologic evaluation [BEL 2, GRADE A].
- The results are expected to influence clinical management [BEL 2, GRADE A].
- As a general rule, testing is not recommended in nodules with established benign or malignant cytologic characteristics [BEL 2, GRADE A].

4.6.2. Molecular testing for cytologically indeterminate nodules

- Cytopathology expertise, patient characteristics, and prevalence of malignancy within the population being tested impact the negative predictive values (NPVs) and positive predictive values (PPVs) for molecular testing [BEL 3, GRADE B].
- Consider the detection of BRAF and RET/PTC and, possibly, PAX8/PPARG and RAS mutations if such tests are available [BEL 2, GRADE B].
- Because of the insufficient evidence and the limited follow-up, we do not recommend either in favor of or against the use of gene expression classifiers (GECs) for cytologically indeterminate nodules [BEL 2, GRADE B].

4.6.3. Role of molecular testing for deciding the extent of surgery

- Currently, with the exception of mutations such as BRAFV600E that have a PPV approaching 100% for papillary thyroid carcinoma, evidence is insufficient to recommend in favor of or against the use of mutation testing as a guide to determine the extent of surgery [BEL 2, GRADE A].

---

### Table 6: Summary Characteristics for Thyroid FNA

<table>
<thead>
<tr>
<th>Feature</th>
<th>Range %</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td>88.2-97.0</td>
<td>Likelihood that patient with disease has positive test results</td>
</tr>
<tr>
<td>Specificity</td>
<td>47.0-98.2</td>
<td>Likelihood that patient without disease has negative test results</td>
</tr>
<tr>
<td>PPV</td>
<td>52.0-98.0</td>
<td>Fraction of patients with positive test results who have disease</td>
</tr>
<tr>
<td>NPV</td>
<td>89.0-96.3</td>
<td>Fraction of patients with negative test results who do not have disease</td>
</tr>
<tr>
<td>False-negative rate</td>
<td>0.5-10.0</td>
<td>FNA negative; histologic findings positive for cancer</td>
</tr>
<tr>
<td>False-positive rate</td>
<td>1.0-7.0</td>
<td>FNA positive; histologic findings negative for cancer</td>
</tr>
</tbody>
</table>

Abbreviations: FNA = fine-needle aspiration; NPV = negative predictive value; PPV = positive predictive value.

4.6.4. How should patients with nodules that are negative at mutation testing be monitored?
• Since the false-negative rate for indeterminate nodules is 5 to 6%, and the experience and follow-up for mutation-negative nodules or nodules classified as benign by a GEC are still insufficient, close follow-up is recommended [BEL 3, GRADE B].

5. Laboratory Evaluation
5.1. Thyroid Hormones
• Always measure serum thyrotropin (TSH) [BEL 1, GRADE A].
• If TSH level is decreased, measure FT$_4$ plus total or FT$_3$; if TSH level is increased, measure FT$_4$ and antithyroid peroxidase antibody (TPOAb) [BEL 2, GRADE A].
• Test for Tg antibody in patients with US or clinical findings suggestive of chronic lymphocytic thyroiditis, when serum levels of TPOAbs are normal [BEL 3, GRADE B].
• Assessment of serum Tg is not recommended in the diagnosis of thyroid nodules [BEL 2, GRADE A].
• In patients undergoing surgery for cancer, a preoperative serum Tg measurement may be considered [BEL 4, GRADE D].
• Perform only TSH receptor antibody (TRAb) measurement for patients with TSH levels below the reference range when Graves disease is suspected [BEL 3, GRADE B].

5.2. Calcitonin
• We do not recommend either in favor of or against the routine determination of serum calcitonin level in the evaluation of thyroid nodules [BEL 3, GRADE B].
• Determine serum calcitonin in thyroid nodules with suspicious US findings or indeterminate cytologic findings [BEL 3, GRADE B].
• Obtain serum calcitonin level for patients with a family history or clinical suspicion of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) [BEL 2, GRADE A].
  o If basal calcitonin level is increased, repeat the test in the absence of possible modifiers [BEL 2, GRADE A].
  o If an elevated (<100 pg/mL) calcitonin level is confirmed, perform a calcium stimulation test to increase the diagnostic accuracy [BEL 3, GRADE C].
• Due to a lack of availability, pentagastrin stimulation is no longer recommended [BEL 3, GRADE C].

5.3. Other Tests
• Measure serum calcium and PTH when a nodular lesion is suggestive of parathyroid adenoma [BEL 3, GRADE B].

6. Radionuclide Scanning
6.1. When to Perform Thyroid Scintigraphy
• In a thyroid nodule or MNG, when the TSH level is below the lower limit of the reference range or when ectopic thyroid tissue or a retrosternal goiter is suspected [BEL 2, GRADE A].
• In iodine-deficient regions, to exclude autonomy of a thyroid nodule or MNG even when the TSH level is low-normal (e.g., 0.5-1.0 mIU/L) [BEL 3, GRADE B].
• Independent of TSH level and whether in iodine-deficient or -sufficient regions, we recommend scintigraphy to evaluate radioiodine therapy eligibility [BEL 2, GRADE B].

6.2. How to Perform Thyroid Scintigraphy
• Use of $^{123}$I, $^{99m}$TcO$_4^-$ (sodium pertechnetate), or technetium sestamibi can be considered for thyroid scintigraphy [BEL 3, GRADE C].
• Sodium iodide $^{131}$I thyroid uptake is not recommended for routine diagnostic use unless low-uptake thyrotoxicosis is suspected [BEL 3, GRADE B].
• If nodules are unchanged at the first US control, repeat the US follow-up after 24 months [BEL 3, GRADE C].
• In asymptomatic nodules with a repeated benign cytology and no suspicious clinical or US features routine follow-up may be avoided [BEL 3, GRADE D].
• In nodules with benign cytology but suspicious clinical or US features, a repeat FNA is recommended [BEL 3, GRADE B].
• In nodules with an increase greater than 50% in volume or that become symptomatic, we recommend repeat FNA [BEL 2, GRADE A].

7.2.2. Medical treatment for benign nodules
• Levothyroxine (LT₄) suppressive therapy is not recommended [BEL 1, GRADE A].
• In geographic areas with mild iodine deficiency, iodine supplementation and/or TSH nonsuppressive LT₄ treatment may be considered for young patients with a small nodular goiter and high-normal TSH levels [BEL 2, GRADE B].
• LT₄ replacement is recommended for young patients with subclinical hypothyroidism or that due to autoimmune thyroiditis [BEL 2, GRADE A].
• LT₄ therapy is not recommended for preventing recurrence after lobectomy when serum TSH stays in the normal range [BEL 2, GRADE A].

7.2.3. Surgical indications for benign nodules
• Consider surgery when local pressure symptoms are present and clearly associated with the nodule(s) or in the case of appearance of suspicious US features, despite benign FNA findings [BEL 2, GRADE B].
• The preferred extent of resection for benign uninodular goiter is lobectomy plus isthmectomy. For MNG, it is (near) total thyroidectomy [BEL 2, GRADE A].

7.2.4. Percutaneous ethanol injection for benign nodules
• Percutaneous ethanol injection (PEI) is a safe and effective outpatient therapy for thyroid cysts and complex nodules with a large fluid component [BEL 1, GRADE A].
• Sample carefully the solid component of complex lesions before doing PEI [BEL 3, GRADE B].
• PEI is recommended as the first-line treatment for relapsing benign cystic lesions [BEL 1, GRADE A].
• PEI is not recommended for solid nodules, whether hyperfunctioning or not, or for MNGs. This procedure may be considered for hot nodules having compressive symptoms only when other treatment modalities are not accessible [BEL 2, GRADE A].

7.2.5. Image-guided thermal ablation for benign nodules
• Consider laser or radiofrequency ablation for the treatment of solid or complex thyroid nodules that progressively enlarge or are symptomatic or cause cosmetic concern [BEL 2, GRADE C].
• Repeat FNA for cytologic confirmation before thermal ablation treatment [BEL 3, GRADE B].
Fig. 2. Thyroid ultrasound features and risk of malignancy.

A) Low-Risk Ultrasound Features
- Thyroid Cyst
- Mostly cystic nodule with reverberating artifacts
- Isoechoic spongiform nodule

B) Intermediate-Risk Ultrasound Features
- Isoechoic nodule with central vascularity
- Isoechoic nodule with macrocalcifications
- Isoechoic nodule with indeterminate hyperechoic spots
- Isoechoic nodule with elevated stiffness on elastography
Radioiodine therapy

7.2.6.1. When and how to perform radioiodine therapy
- Consider radioiodine therapy for hyperfunctioning and/or symptomatic goiter, especially for patients with previous thyroid surgery or at surgical risk and in those who decline surgery [BEL 2, GRADE A].
- Perform FNA before radioiodine therapy on coexistent cold nodules, per the recommendations given for nontoxic MNG [BEL 3, GRADE B].
- Avoid the use of iodine contrast agents or iodinated drugs before administration of radioiodine [BEL 2, GRADE A].
- If possible, withdraw antithyroid drugs 4 to 7 days before treatment and consider resumption 1 week after radioiodine therapy [BEL 2, GRADE B].

7.2.6.2. Contraindications
- Radioiodine is contraindicated in pregnant and breastfeeding females [BEL 2, GRADE A].
- In females of childbearing potential, perform a pregnancy test before radioiodine administration [BEL 2, GRADE A].

7.2.6.3. Follow-up after radioiodine therapy
- Regular thyroid function monitoring is recommended [BEL 2, GRADE A].
- Consider repeat treatment after 3 to 6 months in the case of persistent or recurrent hyperthyroidism or inadequate size reduction [BEL 3, GRADE B].

7.3. Indeterminate Lesions

7.3.1. Management
- Base the management of indeterminate thyroid nodules on their cytologic subclassification, clinical data, and US features [BEL 2, GRADE A].
- Consider elastography for additional information [BEL 2, GRADE B].
- Consider the available technical resources and patient preferences [BEL 4, GRADE D].

7.3.2. Subclasses of indeterminate cytologic findings
- Distinguish, on the basis of morphologic alterations and background component, 2 cytologic subclasses at expected different risk of malignancy, according to the British Thyroid Association System for Reporting Cytopathology classification or to comparable...
cytologic classification systems (see Table 2) [BEL 2, GRADE A].

7.3.2.1. Management of low-risk indeterminate lesions (AUS/FLUS, Thy 3a, or TIR 3A category nodules)

- Consider conservative management in the case of favorable clinical criteria, such as personal or family history, lesion size, and low-risk US and elastography features [BEL 3, GRADE C].
- Repeat FNA for further cytologic assessment and review samples with an experienced cytopathologist [BEL 3, GRADE B].
- CNB may be considered to provide microhistologic information, but routine use is currently not recommended because its role in indeterminate lesions is still unsettled [BEL 3, GRADE C].
- We do not recommend either in favor or against the determination of molecular markers for routine use in this category (see Section 7.6.3.3.) [BEL 3, GRADE D].

7.3.2.2. Management of high-risk indeterminate lesions (FN/SFN, Thy 3f, or TIR 3B category nodules)

- Surgery is recommended for most thyroid lesions in this category [BEL 2, GRADE A].
- Thyroid lobectomy plus isthmectomy is recommended. Total thyroidectomy may be performed, depending on clinical setting, coexistence of contralateral lobe thyroid nodules, and patient preference [BEL 2, GRADE A].
- Frozen sections are usually not useful [BEL 4, GRADE D].
- Consider close clinical follow-up in a minority of cases with favorable clinical and US features, but only after multidisciplinary consultation and discussion of treatment options with the patient [BEL 4, GRADE C].

7.4. Management of FNA-Suspicious Nodules

- Surgical treatment is recommended [BEL 1, GRADE A].
- Repeat FNA in cases with inadequate cellularity or in those that need additional techniques for a better characterization [BEL 3, GRADE B].
- Intraoperative frozen section may be considered [BEL 3, GRADE B].

7.5. Nodules Malignant at FNA

7.5.1. Management

- In the case of differentiated thyroid carcinoma, surgical treatment is recommended [BEL 1, GRADE A].
- For anaplastic thyroid carcinoma, metastatic lesions, and thyroid lymphoma, further diagnostic work-up is recommended before surgical intervention [BEL 2, GRADE A].
7.5.2. Preoperative evaluation

- Review US and cytologic results with the patient, discuss treatment options, and obtain consultation with a surgeon experienced in endocrine surgery [BEL 2, GRADE A].
- US examination of the neck, FNA biopsy of any concomitant suspicious nodule or lymph node, and vocal cord assessment with laryngoscopy are recommended before surgery [BEL 2, GRADE A].
- In the case of suspicious US features, confirm the metastatic nature of a lymph node with measurement of Tg or calcitonin in the washout of the needle used for FNA [BEL 2, GRADE A].
- Consider the use of MRI, CT, and/or 18FDG PET/CT in selected cases with aggressive features for more accurate preoperative staging [BEL 3, GRADE B].

8. Thyroid Nodules During Pregnancy

8.1. Clinical Approach

- Manage thyroid nodules for pregnant subjects in the same way as for nonpregnant subjects [BEL 2, GRADE A].
- When suspicious clinical or US findings are present, we recommend FNA since cytologic diagnostic criteria are not substantially influenced by pregnancy [BEL 2, GRADE A].
- Use of radioactive agents for diagnostic, as well as therapeutic, purposes is contraindicated [BEL 2, GRADE A].
- In the case of subnormal TSH levels during the second half of pregnancy, postpone radionuclide thyroid scan until after delivery and cessation of breastfeeding [BEL 2, GRADE A].
- During pregnancy, TSH-suppressive LT₄ therapy for thyroid nodules or goiter is not recommended [BEL 3, GRADE B]. Iodine supplementation should be used in pregnant females living in iodine-deficient regions [BEL 2, GRADE A].
- For thyroid nodules that grow substantially or become symptomatic during pregnancy, follow-up with US examination is recommended, and if appropriate, FNA is also recommended [BEL 2, GRADE A].
- If FNA shows indeterminate cytologic findings, we recommend US monitoring and postponing surgery until after delivery [BEL 3, GRADE B].

8.2. Management of FNA-Malignant Nodules

- When thyroid malignancy is diagnosed during the first or second trimester, thyroidectomy should be performed during the second trimester [BEL 3, GRADE B].
- For females with clinical or US evidence of extracapsular growth or lymph node metastases, consider surgical treatment during the second trimester of pregnancy [BEL 3, GRADE B].
- Women without evidence of aggressive thyroid cancer may be reassured that surgical treatment performed soon after delivery is unlikely to adversely affect the prognosis. Close clinical and US monitoring is recommended [BEL 3, GRADE B].
- When thyroid malignancy is diagnosed during the third trimester, in absence of aggressive findings, surgical treatment can be deferred until the immediate postpartum period [BEL 3, GRADE C].
- For patients with suspicious or malignant thyroid nodules in whom surgery is postponed until after delivery, we suggest maintenance of TSH at low-normal levels (e.g., 0.5-1.0 mIU/L) [BEL 3, GRADE B].

9. Management of Thyroid Nodules in Children

- Evaluation and management of nodular disease in children are similar to adults [BEL 3, GRADE B].
- Because of a greater prevalence of malignancy in children with thyroid nodules, consider surgical treatment of “cold” as well as hot nodules [BEL 3, GRADE C].

ACKNOWLEDGMENT

AACE/ACE/AME Task Force on Thyroid Nodule Committee Members include the listed authors and Sofia Tseleni Balafouta, MD; Zubair Baloch, MD; Anna Crescenzi, MD; Henning Dralle, MD; Andrea Frasoldati, MD; Roland Gärtner, MD; Rinaldo Guglielmi, MD; Jeffrey I. Mechanick, MD, FACP, FACN, FACE; Christoph Reiners, MD; Istvan Szabolcs, MD, PhD, DSc; Martha A. Zeiger, MD, FACS; and Michele Zini, MD.

DISCLOSURE

AACE/ACE/AME Task Force on Thyroid Nodules

Dr. Zubair Baloch reports that he has received consultant honorarium from Veracyte, Inc.

Dr. Anna Crescenzi reports that she does not have any relevant financial relationships with any commercial interests.

Dr. Henning Dralle reports that he does not have any relevant financial relationships with any commercial interests.

Dr. Andrea Frasoldati reports that he does not have any relevant financial relationships with any commercial interests.
**Dr. Roland Gärtnert** reports that he does not have any relevant financial relationships with any commercial interests.

**Dr. Rinaldo Guglielmi** reports that he does not have any relevant financial relationships with any commercial interests.

**Dr. Jeffrey I. Mechanick** reports that he does not have any relevant financial relationships with any commercial interests.

**Dr. Christoph Reiners** reports that he does not have any relevant financial relationships with any commercial interests.

**Dr. Istvan Szabolcs** reports that he has received speaker honorarium from Berlin-Chemie AG, Genzyme Corporation, and Merck AG.

**Dr. Martha A. Zeiger** reports that she does not have any relevant financial relationships with any commercial interests.

**Dr. Michele Zini** reports that she does not have any relevant financial relationships with any commercial interests.

**Primary Authors**

**Dr. Hossein Gharib** reports that he does not have any relevant financial relationships with any commercial interests.

**Dr. Enrico Papini** reports that he does not have any relevant financial relationships with any commercial interests.

**Dr. Ralf Paschke** reports that he has received speaker honoraria from Merck & Co, Inc, and Sanofi-Aventis U.S., LLC.

**Dr. Daniel S. Duick** reports that he has received speaker honorarium from Genzyme Corporation.

**Dr. Roberto Valcavi** reports that he does not have any relevant financial relationships with any commercial interests.

**Dr. Laszlo Hegedüs** reports that he has received consultant honoraria and research grant support from Novo Nordisk A/S and Genzyme Corporation and consultant and speaker honoraria from Theraclick.

**Dr. Paolo Vitti** reports that he does not have any relevant financial relationships with any commercial interests.

**Dr. Jeffrey R. Garber** reports no disclosures.

**Dr. Mack Harrell** reports no disclosures.

**REFERENCES**


